Effectiveness of a targeted infant RSV immunization strategy (2024–2025): A multicenter matched case-control study in a high-surveillance setting
Open Access
- 21 August 2025
- journal article
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106600
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
This publication has 24 references indexed in Scilit:
- Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Journal of Infection, 2025
- Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial VirusJAMA Network Open, 2025
- Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL studyThe Lancet Infectious Diseases, 2024
- Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infectionsThe Lancet Infectious Diseases, 2024
- Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world studyThe Lancet Infectious Diseases, 2024
- Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case–control study in Paris, FranceThe Lancet Child & Adolescent Health, 2024
- Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling studyThe Lancet Child & Adolescent Health, 2024
- Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal studyThe Lancet Infectious Diseases, 2024
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsThe Lancet Child & Adolescent Health, 2023
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022